Agendia Appoints New CEO and Supervisory Board Member

Irvine, California and Amsterdam (ots/PRNewswire) -

Agendia, an innovative molecular diagnostics company, today
announced that its supervisory board of directors has appointed David
Macdonald as chief executive officer. This follows the resignation of
the company's co-founder and chief executive officer, Dr. Bernhard
Sixt. Dr. Sixt will remain with the company in an advisory capacity.
Agendia also announced the addition of Dr. Colin Goddard, executive
chairman and acting CEO of privately held biotechnology firm Coferon,
Inc., to its supervisory board of directors.

"On behalf of Agendia's board and all its employees, I would like
to personally extend my deepest gratitude to Dr. Sixt for his
leadership in making this company an internationally recognized
innovator in the molecular diagnostic space," said Hessel
Lindenbergh, chairman of Agendia's supervisory board. "David
Macdonald is an accomplished leader in our industry and I have no
doubt that under his leadership, Agendia will continue to thrive."

Macdonald has served as Agendia's COO since April 2010 and brings
with him more than 25 years of international experience developing
and commercializing clinical diagnostics and laboratory services for
companies including Nova Biomedical, Behring Diagnostics, Nichols
Institute and Quest Diagnostics. He has held CEO and COO roles for
the past 18 years. He holds a Bachelor of Science degree from
Northeastern University in management and finance as well as an MBA
from Babson College.

Dr. Goddard served as CEO of OSI Pharmaceuticals, Inc. and as a
member of the company's board of directors until it's $4 billion
acquisition by Astellas Pharmaceuticals, Inc. in July of 2010. He
currently serves as executive chairman and acting CEO of Coferon,
Inc., a privately held biotechnology platform company. He is also a
director of biotechnology companies PanOptica and Human Genome
Sciences, Inc. Dr. Goddard is actively involved as an advisor to
several venture capital firms and other industry groups.

"I'm pleased to welcome Collin Goddard to our supervisory board
of directors. He brings with him a wealth of knowledge in the
biotechnology sector and will be an asset to Agendia moving forward,"
said Lindenbergh.

About Agendia:

Agendia [http://www.agendia.com ] is an international molecular
diagnostic company, focused on the discovery and development of tools
to improve the quality of life for cancer patients, by providing
healthcare professionals with critical information that enables
personalized treatment. Agendia's Symphony(TM) suite of breast cancer
products is based on genomic analysis of an individual patient's
tumor biology, providing unprecedented insight for complex treatment
decisions. Symphony includes MammaPrint, the first and only
FDA-cleared breast cancer recurrence assay, as well as BluePrint, a
molecular subtyping assay, TargetPrint(R), an ER/PR/HER2 expression
assay, and TheraPrint(R), a therapy selection assay. Together, these
tests help physicians determine a patient's individual risk for
metastasis, which patients will benefit from chemo or hormonal
therapy, and which patients do not require these treatments and can
instead be treated with other less arduous and costly methods. For
additional information, please visit http://www.agendia.com.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Public relations contact: Ricochet Public Relations, Jonathan
Lowe, Tel: +1-212-679-3300, ext. 132, Mobile: +1-917-239-2725,
E-mail:
Agendia@RicochetPR.com